Replimune Group presents updated data on RP2 in uveal melanoma

Replimune Group announced updated data from a cohort of metastatic uveal melanoma patients enrolled in the open-label, multicenter, Phase 1 study of RP2 as a single agent and in combination with nivolumab. The data were presented by Dr. Joseph Sacco during a Plenary Session at the 20th International Congress of the Society for Melanoma Research in Philadelphia. Treatment with RP2 led to an overall response rate of 29.4 percent. including responses in patients with liver, lung, and bone metastases. The median duration of response at the data cutoff was 11.47 months. Nearly all patients in the study had progressed on or after immunotherapy with 12 of 17 patients having received both prior anti-PD1 and anti-CTLA-4 therapy, including four of the responding patients. The slides are available on our website under presentations. RP2 was generally well tolerated both as monotherapy and in combination with nivolumab with no additive adverse events observed. The most common grade 1 or 2 treatment related adverse events overall in both cohorts were pyrexia, chills, fatigue, hypotension and pruritis. Six patients had grade 3 TRAEs, including two cases of hypotension. There were no grade 4 or 5 TRAEs.